Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2021 12:40 ET | Source: Vincerx Pharma, Inc.

UPDATE -- Vincerx Pharma Presents Clinical Data on VIP152, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021

VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting Phase 1b study in MYC-Driven relapsed/refractory aggressive...
June 04, 2021 08:00 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021

VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting Phase 1b study in MYC-Driven relapsed/refractory aggressive...
June 03, 2021 16:05 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors

PALO ALTO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
May 26, 2021 08:00 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma to Participate in the Jefferies Virtual Healthcare Conference

PALO ALTO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
May 17, 2021 08:00 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Reports First Quarter 2021 Financial Results and Provides a Corporate Update

Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 First patient in Phase 1b Study of VIP152 in...
May 06, 2021 08:00 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Announces Completion of Public Warrant Redemption

PALO ALTO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) (the “Company”), today announced the completion of its redemption event with respect to its outstanding public...
April 20, 2021 08:00 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Announces FDA Clearance of IND for Phase 1b Study of VIP152 in Chronic Lymphocytic Leukemia and Richter Syndrome

Dose escalation study in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 Vincerx’s second clinical program for potential best-in-class CDK9...
April 10, 2021 08:31 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021

VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models First-in-human studies on track for 1H 2022 PALO ALTO, Calif., April 10, 2021 (GLOBE NEWSWIRE)...
April 07, 2021 08:00 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma To Host Key Opinion Leader Webinar on Bioconjugation and CDK9 Inhibitors for the Treatment of Hematologic and Solid Tumors

PALO ALTO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
April 05, 2021 08:00 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Announces Redemption of Public Warrants

PALO ALTO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) (the “Company”), today announced that it will redeem all of its outstanding public warrants (the “Public...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right